| Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic | Neurology |  | | 2026 | 12 | 41 |
|
| Subjective Cognitive Decline, Inter‐Personal Attachment Style and Relationship Quality | Journal of general and family medicine | | | 2025 | 22 | 162 |
|
| Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease | Neurology | | | 2025 | 18 | 368 |
|
| Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET | European journal of nuclear medicine and molecular imaging | | | 2025 | 20 | 178 |
|
| Resilience in Alzheimer's disease: Impact of operationalization and methodological choices | Alzheimer's & dementia | | | 2025 | 131 | 323 |
|
| Exploring the dimensionality of a neuropsychological test battery in a memory clinic setting using psychometric network analysis | 18th Conference of the Swiss Psychological Society |  | | 2025 | 25 | 2 |
|
| Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE) 18F-FDG-PET pattern in amnestic mild cognitive impairment | European journal of nuclear medicine and molecular imaging | | | 2025 | 21 | 688 |
|
| Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline | Brain | | | 2024 | 12 | 196 |
|
| Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort | Journal of neurology | | | 2024 | 119 | 65 |
|
| A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F]flortaucipir PET in a memory clinic cohort | European journal of nuclear medicine and molecular imaging | | | 2024 | 92 | 93 |
|
| Fingerprints of brain disease : connectome identifiability in Alzheimer's disease | Communications biology | | | 2024 | 208 | 84 |
|
| Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients | Alzheimer's research & therapy | | | 2024 | 158 | 196 |
|
| Insights into single-timepoint ASL hemodynamics: what visual assessment and spatial coefficient of variation can tell | La Radiologia medica | | | 2024 | 80 | 60 |
|
| Alterations in gamma frequency oscillations correlate with cortical tau deposition in Alzheimer’s disease | Neurobiology of aging | | | 2024 | 127 | 205 |
|
| The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline | Alzheimer's & dementia | | | 2024 | 134 | 208 |
|
| Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer's disease | European journal of nuclear medicine and molecular imaging | | | 2023 | 87 | 548 |
|
| Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic | Journal of neurology, neurosurgery and psychiatry | | | 2023 | 274 | 288 |
|
| Prognostic value of imaging-based ATN profiles in a memory clinic cohort | European journal of nuclear medicine and molecular imaging | | | 2023 | 102 | 156 |
|
| Analysis of psychological symptoms following disclosure of amyloid-positron emission tomography imaging results to adults with subjective cognitive decline | JAMA network open | | | 2023 | 100 | 132 |
|
| Patterns of amyloid accumulation in amyloid-negative cases | Neurobiology of aging | | | 2023 | 81 | 33 |
|
| ATN profile classification across two independent prospective cohorts | Frontiers in medicine | | | 2023 | 141 | 189 |
|
| Dementia prevention in memory clinics : recommendations from the european task force for brain health services | The Lancet regional health. Europe | | | 2023 | 123 | 288 |
|
| Early-phase 18F-Florbetapir and 18F-Flutemetamol images as proxies of brain metabolism in a memory clinic setting | The Journal of nuclear medicine | | | 2023 | 185 | 308 |
|
| Exploring the structure of a neuropsychological assessment with cognitively healthy adults | 17 th Conference of the Swiss Psychological Society | | | 2022 | 190 | 8 |
|
| The probabilistic model of Alzheimer disease: the amyloid hypothesis revised | Nature reviews. Neuroscience | | | 2022 | 172 | 1 |
|
| Simulad: a dynamical model for personalized simulation and disease staging in alzheimer's disease | Neurobiology of aging | | | 2022 | 141 | 72 |
|
| The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging | Journal of Alzheimer's disease | | | 2022 | 217 | 169 |
|
| Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study | Magnetic resonance imaging | | | 2021 | 112 | 0 |
|
| Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6 | Alzheimer's research & therapy | | | 2021 | 189 | 408 |
|
| Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison | European Journal of Nuclear Medicine and Molecular Imaging | | | 2021 | 348 | 250 |
|
| Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design | Alzheimer's Research and Therapy | | | 2021 | 452 | 485 |
|
| Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6 | Alzheimer's research & therapy | | | 2021 | 229 | 347 |
|
| Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services — part 2 of 6 | Alzheimer's research & therapy | | | 2021 | 171 | 404 |
|
| Protocols for cognitive enhancement. a user manual for brain health services — part 5 of 6 | Alzheimer's research & therapy | | | 2021 | 164 | 248 |
|
| Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus: Linking Functional Connectivity and Clinical Outcome | Journal of Alzheimer's disease | | | 2021 | 219 | 0 |
|
| Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services — part 6 of 6 | Alzheimer's research & therapy | | | 2021 | 133 | 169 |
|
| Dementia risk communication. A user manual for Brain Health Services — part 3 of 6 | Alzheimer's research & therapy | | | 2021 | 140 | 273 |
|
| Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study | Aging Clinical and Experimental Research | | | 2020 | 460 | 1 |
|
| CSF cutoffs for MCI due to AD depend on APOEε4 carrier status | Neurobiology of Aging | | | 2020 | 297 | 2 |
|
| Comparison of Bioinformatics Pipelines and Operating Systems for the Analyses of 16S rRNA Gene Amplicon Sequences in Human Fecal Samples | Frontiers in Microbiology | | | 2020 | 449 | 252 |
|
| The A/T/N model applied through imaging biomarkers in a memory clinic | European Journal of Nuclear Medicine and Molecular Imaging | | | 2019 | 430 | 6 |
|
| Is a large-scale screening for Alzheimer's disease possible? yes, in a few years | The Journal of Prevention of Alzheimer's Disease | | | 2019 | 312 | 7 |
|
